Plasma Carnitine Level in Peripheral Arterial Disease

The plasma carnitine fraction, which involves in skeletal muscle metabolism, was measured in 130 patients with peripheral arterial disease (PAD). The ratios of acyl carnitine and free carnitine (carnitine ratio) are 0.42 ± 0.22 in patients with critical limb ischemia (CLI) and 0.26 ± 0.13 in patients with intermittent claudication (IC), respectively, being significantly high in the patients with CLI (p < 0.01). Even in omitted hemodialysis patients, the carnitine ratio is higher in the patients with CLI than in the patients with IC (0.31 ± 0.14 vs. 0.24 ± 0.10, p < 0.05). When the multivariate analysis was performed using gender, diabetes, dyslipidemia, chronic hemodialysis as the explanatory variables, dialysis (p < 0.001) and CLI (p < 0.01) are shown to be the significant determinant factors of carnitine ratio. These results indicate that carnitine metabolism is deeply related to the severity of ischemia in the muscle. The carnitine ratio may become a marker of severity of limb ischemia of PAD and a possible indicator of preclinical CLI. :

[1]  Michelle D. Miller,et al.  A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication. , 2013, Atherosclerosis.

[2]  R. Ringseis,et al.  Mechanisms underlying the anti-wasting effect of l-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies , 2013, European Journal of Nutrition.

[3]  A. Rigoni,et al.  Propionyl-L-Carnitine Improves Endothelial Function, Microcirculation and Pain Management in Critical Limb Ischemia , 2012, Cardiovascular Drugs and Therapy.

[4]  G. Novo,et al.  Pharmacological Treatment of Patients with Chronic Critical Limb Ischemia: L-Propionyl-Carnitine Enhances the Short-Term Effects of PGE-1 , 2009, Cardiovascular Drugs and Therapy.

[5]  W. Hiatt Carnitine and Peripheral Arterial Disease , 2004, Annals of the New York Academy of Sciences.

[6]  J. Cooke,et al.  Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. , 2001, The American journal of medicine.

[7]  C. Diehm,et al.  European multicenter study on propionyl-L-carnitine in intermittent claudication. , 1999, Journal of the American College of Cardiology.

[8]  M. Condorelli,et al.  Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. , 1995, Journal of the American College of Cardiology.

[9]  R. Carrozzo,et al.  Muscle Carnitine Deficiency in Patients With Severe Peripheral Vascular Disease , 1991, Circulation.

[10]  P. Walker Carnitine metabolism during exercise in patients with peripheral vascular occlusive disease:Hiatt WR, Nawaz D, Brass EP. J Appl Physiol 1987; 62:2383–2387 , 1988 .

[11]  W. Hiatt,et al.  Carnitine metabolism during exercise in patients with peripheral vascular disease. , 1987, Journal of applied physiology.

[12]  J. Bremer Carnitine--metabolism and functions. , 1983, Physiological reviews.

[13]  A. Evans,et al.  Pharmacokinetics of L-Carnitine , 2003, Clinical pharmacokinetics.